Personalis Inc Stock
Price
Target price
€1.14
€1.14
-1.620%
-0.018
-1.620%
€3.26
27.06.24 / Tradegate
WKN: A2PLTK / Symbol: PSNL / Name: Personalis / Stock / Biotechnology & Medical Research / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Personalis Inc Stock
A loss of -1.620% shows a downward development for Personalis Inc.
We see a rather positive sentiment for Personalis Inc with 8 Buy predictions and 1 Sell predictions.
With a target price of 3 € there is potential for a 164.08% increase which would mean more than doubling the current price of 1.14 € for Personalis Inc.
Our community identified positive and negative aspects for Personalis Inc stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Personalis Inc stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Personalis Inc in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Personalis Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Personalis Inc | -1.620% | -3.319% | -5.569% | -33.722% | -45.385% | -94.549% | - |
| Stoke Therapeutics Inc | 3.170% | -3.008% | -4.444% | - | - | - | - |
| Immuron | -7.770% | -6.863% | -5.941% | 17.284% | 13.772% | -50.262% | - |
Comments
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $3.50 price target on the stock.
Show more
Ratings data for PSNL provided by MarketBeat
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $3.50 price target on the stock.
Show more
Ratings data for PSNL provided by MarketBeat
Personalis, Inc. (NASDAQ: PSNL) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $4.00 price target on the stock.
Show more
Ratings data for PSNL provided by MarketBeat
News
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
Personalis, Inc. (Nasdaq: PSNL) announced today that data presented at the American Society for Clinical Oncology (ASCO) oral podium talks in Chicago, IL demonstrated that the Personalis NeXT
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal®, Personalis’
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company’s NeXT